Figure 4 | Scientific Reports

Figure 4

From: Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing

Figure 4The alternative text for this image may have been generated using AI.

Analytical characterization of PF-06645849. (a) DSC traces of Fc-FGF21 [N171] (solid black line) and Fc-FGF21 [N171][R19V] (solid red line) in PBS. Mid-point transition temperature fits are shown in dashed lines. (b) Western blot analysis of purified PF-06645849 produced in CHO cell lines. Lane 1, post ProteinA elution; lane 2, post ButylFF (GE) flow-through step. (c) Mass spec glycan analysis of PF-06645849 after removal of Fc sugar using IgGZero enzyme. IgGZero hydrolyzes the β1,4 linkage between the core GlcNAc residues in the Fc-glycan, leaving the innermost GlcNAc intact on the Fc (peak labeled 2x). Remaining Glycan structures derived from [N171] are assigned to the corresponding m/z values. (d) pERK phosphorylation assay of WT FGF21, PF-05231023, and HEK- and CHO-produced PF-06645849. Values presented are Mean ± SD (n = 4).

Back to article page